temozolomide has been researched along with su 11248 in 20 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (15.00) | 29.6817 |
2010's | 12 (60.00) | 24.3611 |
2020's | 5 (25.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Gallo, JM; Guo, P; Zhou, Q | 1 |
Gallo, JM; Zhou, Q | 1 |
Schiff, D; van den Bent, MJ; Wen, PY | 1 |
Abdulkarim, B; Aghi, M; Chahal, M; Christensen, JG; Famulski, K; Graham, K; Jacques, A; Lesniak, D; Murray, D; Sabri, S; Xu, Y | 1 |
Eriksson, B | 1 |
Reidy-Lagunes, D; Thornton, R | 1 |
Dreyer, C; Faivre, S; Raymond, E | 1 |
Igarashi, H; Ito, T; Jensen, RT; Takayanagi, R | 1 |
Auf, G; Bayerl, SH; Broggini, T; Bruenner, J; Czabanka, M; Harms, C; Harms, U; Heppner, FL; Jabouille, A; Koch, A; Kremenetskaia, I; Mueller, S; Nieminen, M; Parmaksiz, G; Topalovic, M; Vajkoczy, P | 1 |
Bozzi, F; Casali, PG; Cominetti, D; Gronchi, A; Libertini, M; Messina, A; Morosi, C; Negri, T; Palassini, E; Pilotti, S; Stacchiotti, S; Tamborini, E; Tortoreto, M; Zaffaroni, N | 1 |
Corbacioglu, S; Debatin, KM; Engelke, J; Fulda, S; Halatsch, ME; Karpel-Massler, G; Nonnenmacher, L; Simmet, T; Westhoff, MA | 1 |
Du Four, S; Duerinck, J; Everaert, H; Hau, P; Michotte, A; Neyns, B; Sander, W; Van Binst, AM | 1 |
Campanella, R; Caroli, M; Cordiglieri, C; Crisà, FM; Guarnaccia, L; La Verde, N; Locatelli, M; Marfia, G; Miozzo, M; Navone, SE; Rampini, P; Riboni, L; Schisano, L | 1 |
Amoroso, V; Berruti, A; Bertani, E; Cella, CA; Fazio, N; Laffi, A; Maisonneuve, P; Pellicori, S; Pozzari, M; Spada, F | 1 |
Andreasi, V; April-Monn, SL; Capurso, G; Di Domenico, A; Doglioni, C; Falconi, M; Gloor, B; Kim-Fuchs, C; Maire, R; Marinoni, I; Muffatti, F; Partelli, S; Perren, A; Schiavo Lena, M; Skowronska, M; Trippel, M; Wiedmer, T; Zatelli, MC | 1 |
Chen, KC; Chen, PH; Cheng, CH; Ho, KH; Lee, YT; Shih, CM | 1 |
Dong, J; Gao, H; Li, H; Liu, L; Ni, Q; Wang, W; Xu, H; Ye, L; Zhang, W | 1 |
Beuschlein, F; Crona, J; Grossman, AB; Nölting, S; Pacak, K; Wang, K | 1 |
Auernhammer, CJ; Bechmann, N; Beuschlein, F; Bornstein, SR; Dischinger, U; Fischer, A; Fliedner, SMJ; Grossman, AB; Hantel, C; Kloos, S; Kroiss, M; Maurer, J; Mohr, H; Nölting, S; Pacak, K; Pamporaki, C; Pellegata, NS; Reincke, M; Remde, H; Reul, A; Robledo, M; Timmers, HJLM; Wang, K | 1 |
7 review(s) available for temozolomide and su 11248
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Neurological adverse effects caused by cytotoxic and targeted therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dacarbazine; Drug Approval; Epothilones; Humans; Imatinib Mesylate; Indoles; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Piperazines; Pyrazines; Pyrimidines; Pyrroles; Sunitinib; Temozolomide; Tubulin Modulators; United States; United States Food and Drug Administration | 2009 |
New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
Topics: Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Everolimus; Fluorouracil; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Treatment Outcome | 2010 |
Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoid Tumor; Combined Modality Therapy; Dacarbazine; Embolization, Therapeutic; Everolimus; Humans; Immunosuppressive Agents; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Streptozocin; Sunitinib; Temozolomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors; Yttrium Radioisotopes | 2012 |
[Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
Topics: Antineoplastic Agents; Dacarbazine; Digestive System Surgical Procedures; Everolimus; Humans; Immunosuppressive Agents; Indoles; Japan; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Somatostatin; Streptozocin; Sunitinib; Temozolomide | 2012 |
Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cytoreduction Surgical Procedures; Humans; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Radiopharmaceuticals; Sunitinib; Temozolomide; Vascular Endothelial Growth Factor A | 2018 |
Targeted Therapies in Pheochromocytoma and Paraganglioma.
Topics: Adrenal Gland Neoplasms; Humans; Paraganglioma; Pheochromocytoma; Randomized Controlled Trials as Topic; Sunitinib; Temozolomide | 2022 |
1 trial(s) available for temozolomide and su 11248
Article | Year |
---|---|
Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioma; Humans; Indoles; Lomustine; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrroles; Sunitinib; Survival Rate; Temozolomide | 2015 |
12 other study(ies) available for temozolomide and su 11248
Article | Year |
---|---|
Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Collagen; Collagen Type IV; Dacarbazine; Drug Combinations; Glioma; Immunoenzyme Techniques; Indoles; Laminin; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Proteoglycans; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sunitinib; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Interactions; Glioma; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Indoles; Male; Mice; Mice, Nude; Pyrroles; Sunitinib; Temozolomide; Tissue Distribution; Xenograft Model Antitumor Assays | 2009 |
MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Separation; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression; Gene Expression Profiling; Glioblastoma; Humans; Indoles; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Radiotherapy; Reverse Transcriptase Polymerase Chain Reaction; Sunitinib; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2010 |
Targeting neuroendocrine tumor: mixing standard options with novel therapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Humans; Indoles; Medical Oncology; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib; Temozolomide; Treatment Outcome | 2012 |
Combined temozolomide and sunitinib treatment leads to better tumour control but increased vascular resistance in O6-methylguanine methyltransferase-methylated gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Dacarbazine; DNA Methylation; DNA, Neoplasm; Glioma; Heterografts; Humans; Indoles; Male; Mice; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Pyrroles; Sunitinib; Temozolomide; Tumor Cells, Cultured; Vascular Resistance | 2013 |
Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Male; Mice; Mice, SCID; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Solitary Fibrous Tumors; Sulfonamides; Sunitinib; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
RIST: a potent new combination therapy for glioblastoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Child; Dacarbazine; Female; Glioblastoma; Humans; Indoles; Irinotecan; Male; Membrane Potential, Mitochondrial; Mice, Inbred NOD; Molecular Targeted Therapy; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Aspirin; bcl-2-Associated X Protein; Bevacizumab; Blotting, Western; Brain Neoplasms; Cell Survival; Drug Synergism; Endothelial Cells; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mitogen-Activated Protein Kinase Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; ras Proteins; Real-Time Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sunitinib; Temozolomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cryopreservation; Drug Screening Assays, Antitumor; Everolimus; Humans; Islets of Langerhans; Neuroendocrine Tumors; Pancreatic Neoplasms; Primary Cell Culture; Proof of Concept Study; Sunitinib; Temozolomide | 2021 |
Guanabenz Sensitizes Glioblastoma Cells to Sunitinib by Inhibiting GADD34-Mediated Autophagic Signaling.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Computer Simulation; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gene Expression Profiling; Glioblastoma; Guanabenz; Humans; Mice; Molecular Targeted Therapy; Neoplasm Transplantation; Protein Kinase Inhibitors; Protein Phosphatase 1; RNA-Seq; Sunitinib; Temozolomide; Up-Regulation | 2021 |
Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoembolization, Therapeutic; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Retrospective Studies; Sunitinib; Temozolomide | 2022 |
Responses to systemic therapy in metastatic pheochromocytoma/paraganglioma: a retrospective multicenter cohort study.
Topics: Adrenal Gland Neoplasms; Brain Neoplasms; Cardiovascular Diseases; Cohort Studies; Humans; Iodine Radioisotopes; Neoplasms, Second Primary; Paraganglioma; Pheochromocytoma; Retrospective Studies; Somatostatin; Succinate Dehydrogenase; Sunitinib; Temozolomide | 2023 |